Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Jul 27

PMID 39063598

Authors

Amani Elshaer

David M H Chascsa

Blanca C Lizaola-Mayo

Affiliations

Soon will be listed here.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.

Citing Articles

subsp. CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice.

Jang H, Joung H, Chu J, Cho M, Kim Y, Kim K Nutrients. 2025; 16(24.

PMID: 39770882 PMC: 11677567. DOI: 10.3390/nu16244260.

Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target.

Milani I, Codini M, Guarisco G, Chinucci M, Gaita C, Leonetti F Int J Mol Sci. 2024; 25(19).

PMID: 39409124 PMC: 11477334. DOI: 10.3390/ijms251910795.

Knock-Out of IKKepsilon Ameliorates Atherosclerosis and Fatty Liver Disease by Alterations of Lipid Metabolism in the PCSK9 Model in Mice.

Weiss U, Mungo E, Hass M, Benning D, Gurke R, Hahnefeld L Int J Mol Sci. 2024; 25(19).

PMID: 39409049 PMC: 11476531. DOI: 10.3390/ijms251910721.

References

Wang X, Wang L, Geng L, Tanaka N, Ye B . Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner. Int J Mol Sci. 2023; 24(6). PMC: 10058113. DOI: 10.3390/ijms24065843. View

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View

Pan C, Stanley T . Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne). 2020; 11:70. PMC: 7046622. DOI: 10.3389/fendo.2020.00070. View

Armandi A, Bugianesi E . Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease. Eur J Intern Med. 2024; 122:20-27. DOI: 10.1016/j.ejim.2024.01.005. View

Paniagua J, Gallego de la Sacristana A, Sanchez E, Romero I, Vidal-Puig A, Berral F . A MUFA-rich diet improves posprandial glucose, lipid and GLP-1 responses in insulin-resistant subjects. J Am Coll Nutr. 2007; 26(5):434-44. DOI: 10.1080/07315724.2007.10719633. View

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Zhou X, Yu J, Li L, Gloy V, Nordmann A, Tiboni M . Effects of Bariatric Surgery on Mortality, Cardiovascular Events, and Cancer Outcomes in Obese Patients: Systematic Review and Meta-analysis. Obes Surg. 2016; 26(11):2590-2601. DOI: 10.1007/s11695-016-2144-x. View

Mellinger J, Shedden K, Winder G, Fernandez A, Lee B, Waljee J . Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse. Liver Int. 2021; 41(5):1012-1019. PMC: 8204517. DOI: 10.1111/liv.14805. View

Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z . Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2010; 54(6):1214-23. DOI: 10.1016/j.jhep.2010.09.032. View

10.

Eisenberg D, Shikora S, Aarts E, Aminian A, Angrisani L, Cohen R . 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022; 18(12):1345-1356. DOI: 10.1016/j.soard.2022.08.013. View

11.

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

12.

Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y . Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018; 7(4):1070-1080. PMC: 5911601. DOI: 10.1002/cam4.1354. View

13.

Allen A, Hicks S, Mara K, Larson J, Therneau T . The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study. J Hepatol. 2019; 71(6):1229-1236. PMC: 6921701. DOI: 10.1016/j.jhep.2019.08.018. View

14.

Le M, Le D, Baez T, Wu Y, Ito T, Lee E . Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023; 79(2):287-295. DOI: 10.1016/j.jhep.2023.03.040. View

15.

Jiang Z, Feldbrugge L, Tapper E, Popov Y, Ghaziani T, Afdhal N . Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Aliment Pharmacol Ther. 2016; 43(6):734-43. DOI: 10.1111/apt.13515. View

16.

Paik J, Henry L, de Avila L, Younossi E, Racila A, Younossi Z . Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States. Hepatol Commun. 2019; 3(11):1459-1471. PMC: 6824058. DOI: 10.1002/hep4.1419. View

17.

Harrison S, Ratziu V, Anstee Q, Noureddin M, Sanyal A, Schattenberg J . Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023; 59(1):51-63. DOI: 10.1111/apt.17734. View

18.

Suzuki Y, Maekawa S, Yamashita K, Osawa L, Komiyama Y, Nakakuki N . Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol. 2023; 38(6):921-929. DOI: 10.1111/jgh.16154. View

19.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

20.

Lee H, Lee H, Kim E, Kim H, Kim H, Ahn S . Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2023; 73(3):533-540. DOI: 10.1136/gutjnl-2023-331003. View